Lv511
1010 积分 2024-10-11 加入
Simultaneous Covalent Modification of K-Ras(G12D) and K-Ras(G12C) with Tunable Oxirane Electrophiles
5天前
已完结
Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer
5天前
已完结
Abstract 932: Discovery of D-1553, a novel and selective KRas-G12C Inhibitor with potent anti-tumor activity in a broad spectrum of tumor cell lines and xenograft models
5天前
已关闭
Discovery of MK-1084: An Orally Bioavailable and Low-Dose KRASG12C Inhibitor
5天前
已完结
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers
5天前
已完结
Identification of potential inhibitors, conformational dynamics, and mechanistic insights into mutant Kirsten rat sarcoma virus (G13D) driven cancers
6天前
已完结
CSC01 shows promise as a potential inhibitor of the oncogenic G13D mutant of KRAS: an in silico approach
6天前
已完结
Structure-Based Design and Evaluation of Reversible KRAS G13D Inhibitors
6天前
已完结
Abstract 1260: First-in-class, orally bioavailable KRASG12V(ON) tri-complex inhibitors, as single agents and in combinations, drive profound anti-tumor activity in preclinical models of KRASG12V mutant cancers
6天前
已完结
Covalent inhibitors of K-Ras G12S, G12R, and G12D
6天前
已完结
皖公网安备34019202002308
